In order to develop orally active CCR5 antagonists, we investigated 1-benzoxepine derivatives containing new polar substituents, such as phosphonate, phosphine oxide or pyridine N-oxide moieties, as replacements for the previoiusly reported quaternary ammonium moiety. Among these compounds, the 2-(a a-hydroxybenzyl)pyridine N-oxide 5e exhibited moderate CCR5 antagonistic activity and had an acceptable pharmacokinetic profile in rats. Subsequent chemical modification was performed and compound (S)-5f possessing the (S)-configuration hydroxy group was found to be more active than the (R)-isomer. Replacement of the 1-benzoxepine ring with a 4-methylphenyl group by a 1-benzazepine ring with a 4-[2-(butoxy)ethoxy]phenyl group enhanced the activity in the binding assay. In addition, introduction of a 3-trifluoromethyl group on the phenyl group of the anilide moiety led to greatly increased activity in the HIV-1 envelope-mediated membrane fusion assay. In particular, compound (S)-5s showed the most potent CCR5 antagonistic activity (IC 50 ‫2.7؍‬ nM) and inhibitory effect (IC 50 ‫4.5؍‬ nM) in the fusion assay, together with good pharmacokinetic properties in rats.
Currently, human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors and protease inhibitors are used for the treatment of HIV-1 infection. Although combination chemotherapy, which uses these two types of anti-HIV-1 agents, has been successful for suppression of viral load in HIV-1 infected individuals and reduction of mortality, 1) it has been found that it can not achieve virus eradication.
2) Therefore, new anti-HIV-1 agents that target other events in the HIV-1 replication cycle are necessary and recently, inhibition against HIV-1 cell entry or fusion, the first stage of the HIV-1 life cycle, is considered to be an attractive target for viral coreceptor antagonists, gp120-mediated CD4 binding inhibitors and gp41-mediated HIV-1 fusion inhibitors.
3) Among these targets, the CC chemokine receptor 5 (CCR5), a coreceptor for macrophage-tropic (R5) HIV-1 cell entry, [4] [5] [6] [7] [8] attracts many research groups to develop its antagonists. 9) The compound 1, which we first reported as a small molecule CCR5 antagonist, exhibited highly potent anti-HIV-1 activity. 10, 11) However, its oral absorption was very poor because of its polar quaternary ammonium moiety. In order to develop an orally active CCR5 antagonist, chemical modification of the tertiary amine derivative was performed, which led to the discovery of the orally active 1-benzothiepine 1,1-dioxide (3) and 1-benzazepine (4) derivatives. 12, 13) In our previous paper, we described that incorporation of a 2-(butoxy)-ethoxy group at the 4-position on the 7-phenyl group of the [6, 7] fused nucleus resulted in both enhanced activity and improved pharmacokinetic profiles, and introduction of an isobutyl or 1-methylpyrazol-4-ylmethyl group as the 1-substituent on the 1-benzazepine ring further increased the activity. 13) We also searched for other polar substituents to replace the quaternary ammonium moiety, and in our first paper, we reported a phosphonium salt 2 as a lead compound of smallmolecule CCR5 antagonists. 11) We have now designed and synthesized the anilide derivatives 5, containing phosphonate, phosphine oxide or pyridine N-oxide moieties as new polar substituents to replace the phosphonium salt and quaternary ammonium salt moieties, and have examined their inhibitory effects on chemokine binding (Fig. 1) . In this paper, The target compounds 5a, b were prepared according to Chart 6. Coupling reaction of the 1-benzoxepine-4-carboxylic acid 19a 11) with the corresponding anilines 8a, b by the acid chloride method afforded the target phosphonate 5a and phospine oxide 5b.
Orally Active CCR5 Antagonists as Anti-HIV-1 Agents 2: Synthesis and Biological Activities of Anilide Derivatives Containing a Pyridine N-Oxide Moiety
Synthesis of the target pyridine N-oxide compounds 5c-f containing the 1-benzoxepine or 1,1-dioxo-1-benzothiepine ring moieties is illustrated in Chart 7. Conversion of the carboxylic acids 19a, 11) b 13) into acid chlorides and subsequent coupling with the aniline derivatives 8c-e gave the anilide derivatives 20a-d containing the pyridine moieties. The target pyridine N-oxide derivatives 5c-f were prepared by mCPBA oxidation of the pyridine derivatives 20a-d.
The target 1-benzazepine derivatives 5g-s were prepared according to Chart 8. Alkaline hydrolysis of the ester 21, 13) followed by trifluoroacetylation of the resulting carboxylic acid 22 gave 1-trifluoroacetyl-1-benzazepine-4-carboxylic acid 23. Coupling reaction of the carboxylic acid 23 with the aniline derivatives 8e-m using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBt), followed by mCPBA oxidation gave the pyridine N-oxide derivatives 25a-i containing the N-trifluoroacetyl protected 1-benzazepine moiety. The target pyridine N-oxide derivatives 5g-s were prepared by removal of the N-trifluoroacetyl group of 25a-i using sodium borohydride (NaBH 4 ) 17) and subsequent reductive amination of the resulting 26a-i with the appropriate aldehydes.
18) The optically active compounds (S)-5s and (R)-5s were obtained by optical resolution of racemate 5s utilizing chiral HPLC.
Biological Results and Discussion
The compounds prepared were evaluated for their inhibitory effects on chemokine binding to CCR5-expressing CHO cells. Binding reactions were performed in the presence of [ Tables 1 and 2 as IC 50 values. The compounds with potent binding inhibitory activity were further evaluated for their inhibitory effects on an HIV-1 envelope (Env)-mediated membrane fusion. The membrane fusion assay was carried out using R5 HIV-1 (JR-FL strain) Env-expressing COS-7 cells and CCR5-expressing MOLT-4 cells. The results are summarized in Table 3 as IC 50  values. First of all, the search for new polar substituents to replace the quaternary ammonium moiety was performed while keeping the 7-(4-methylphenyl)-1-benzoxepine moiety, which contributed to the appearance of potent activity, as well as the benzocycloheptane moiety of the quaternary ammonium de-rivatives. Based on our experience, we designed derivatives with 6-membered phosphonate, phosphine oxide or pyridine N-oxide moieties as the polar substituents and examined their inhibitory effects on chemokine binding (Table 1) . The compounds with the polar phosphonate (5a) and phosphine oxide (5b) moieties inhibited the binding with IC 50 values of 0.40 mM and 0.41 mM, respectively. However, the biaryl type pyridine N-oxide derivative 5c exhibited weak inhibitory activity. Insertion of the methylene group (5d) between the pyridine and benzene moieties of 5c resulted in a moderate increase of activity. Interestingly, introduction of a hydroxy group onto the methylene of 5d led to further enhancement of activity, and the compound 5e was as active as the phosphonate 5a and phosphine oxide 5b. It was considered that a further increase of polarity by introduction of a hydroxy group in the neighborhood of the pyridine N-oxide moiety might contribute to improving the binding capability of the active site. From the results of preliminary pharmacokinetic studies in SD (IGS) rats, it was found that the pyridine Noxide derivative 5e exhibited the best oral absorption among the compounds (5a, b, e) (details not shown). Thus, its C max and AUC 0-24 h values were 0.09 mg/ml and 1.14 mg · h/ml (10 mg/kg, p.o.), respectively. Therefore, we selected the 2-(a-hydroxybenzyl)pyridine N-oxide moiety as a new polar substituent to replace the quaternary ammonium moiety. For the previous tertiary amine derivatives, we described that both replacement of the 1-benzoxepine ring with the 1,1-dioxo-1-benzothiepine or a 1-(bulky)alkyl-1-benzazepine ring and substitution with the 2-(butoxy)ethoxy group at the 4-position on the phenyl group of the [6, 7] fused nucleus, increased the activity. Therefore, we investigated the 1,1-dioxo-1-benzothiepine or 1-alkyl-1-benzazepine with the 4-[2-(butoxy)ethoxy]phenyl group in place of the 1-benzoxepine with the 4-methylphenyl group. The effect of the configuration of the hydroxy group was first examined, keeping the 1,1-dioxo-1-benzothiepine moiety. As shown in Table 2 , compound (S)- 5f possessing the (S)-configuration hydroxy group was about 8 times more active than the (R)-isomer (R)-5f, which indicated that not only the pyridine N-oxide moiety but also the (S)-configuration hydroxy group was necessary for inhibitory activity. Although the optically active 1-benzothiepine 1,1-dioxide (S)-5f was as active as the racemic 1-benzoxepine 5e, the 1-propyl-1-benzazepine (S)-5g enhanced the activity about 11 times. Secondly, we also examined the effects of the 1-substituent on the 1-benzazepine ring (Table 2 ). Consequently, the 1-cyclopropylmethyl compound (S)-5i was found to be as active as the propyl compound (S)-5g. Replacement of the propyl group with the isobutyl ((S)-5h), benzyl ((S)-5j) or 1-methylpyrazol-4-ylmethyl ((S)-5k) group led to slight increase of activity. These results were generally similar to those of the tertiary amine derivatives. Next, the inhibitory effects of the compounds (S)-5h and (S)-5k on the HIV-1 Env-mediated membrane fusion were tested. As shown in Table 3 , the inhibitory effects in the fusion assay were significantly weaker than those in the binding assay.
In an attempt to alter the activity in the fusion assay, we tried to sterically cover some parts of the 2-(a-hydroxybenzyl)pyridine N-oxide moiety. Namely, assuming that activity might be related to protein binding in the fusion assay, we investigated introduction of substituents on the pyridine ring and benzene ring of the anilide moiety. We selected the isobutyl group as the 1-substituent on the 1-benzazepine ring considering activity, ease of synthesis and molecular weight, and the racemic compounds 5l-s were prepared and tested ( Table 2 ). Introduction of a methyl group at the 4-position on the pyridine ring (5m) retained the activity in the binding assay, whereas substitution of a methyl group at the 3-, 5-or 6-position (5l, n, o) decreased the activity. Introduction of a methyl (5p), methoxy (5q) or chloro (5r) group at the 3-position on the benzene ring, neighboring the hydroxy group, retained the activity. Compound 5s with a trifluoromethyl group at the same position was as active as compound (S)-5h. Optically active compound (S)-5s showed highly potent inhibitory activity (IC 50 ϭ7.2 nM), and was about 6 times more active then the (R)-isomer. Additionally, the inhibitory effects of the compounds [5m, 5p-r, (S)-5s], with potent binding inhibitory activity, on the HIV-1 Env-mediated membrane fusion were examined ( Table 3) . Introduction of substituents onto the 2-(a-hydroxybenzyl)pyridine N-oxide moiety was generally effective in the fusion assay, when compared with compound (S)-5h, which showed activity about 270 times lower than that of the binding assay. The 4-methylpyridine N-oxide 5m inhibited the membrane fusion with an IC 50 value of 170 nM. Compound 5p, with 3-methyl group on the phenyl group, exhibited moderate activity. Surprisingly, introduction of a 3-trifluoromethyl group on the phenyl group, led to a great enhancement of activity. Thus, optically active compound (S)-5s strongly inhibited the membrane fusion with an IC 50 value of 5.4 nM, and the effect was equivalent to that in the binding assay. Compound (S)-5s showed highly potent effects both in the binding and fusion assays, comparable to the quaternary ammonium compound 1.
Finally, preliminary pharmacokinetic studies of compound (S)-5s were investigated. Compound (S)-5s was orally administered at 10 mg/kg to SD (IGS) rats and the results are indicated in Table 4 . The C max and AUC 0-24 h values of compound (S)-5s were 2.33 mg/ml and 33.1 mg · h/ml, respectively, and compound (S)-5s exhibited high plasma level in rats.
Conclusion
In order to develop orally active CCR5 antagonists, a search for polar substituents, such as phosphonate, phosphine oxide and pyridine N-oxide moieties, to replace the quaternary ammonium moiety of the anilide derivative 1 was performed. Among the 1-benzoxepine and 1-benzothiepine 1,1-dioxide derivatives containing the polar substituents, it was found that the 2-(a-hydroxybenzyl)pyridine N-oxide showed CCR5 antagonistic activity and oral absorption in rats, and that the compound possessing the (S)-configuration hydroxy group was more active than the (R)-isomer. Further investigation of the 2-(a-hydroxybenzyl)pyridine N-oxide derivatives containing the 1-benzazepine moiety led to discovering that introduction of a trifluoromethyl group at the 3-position on the phenyl group significantly enhanced activity in the HIV-1 Env-mediated membrane fusion assay. In particular, the optically active compound (S)-5s exhibited highly potent CCR5 antagonistic activity and inhibitory effect on the membrane fusion, comparable to compound 1, together with good pharmacokinetic properties in rats. These results showed the possibility that the (S)-2-(a-hydroxybenzyl)pyridine N-oxide moiety might replace the tertiary amine moiety as a polar 822
Vol. 52, No. 7 substituent for orally active CCR5 antagonists.
Experimental
Melting points were determined on a Yanagimoto micro melting point apparatus, and are uncorrected. Proton nuclear magnetic resonance ( 1 H-NMR) spectra were recorded on a Varian Gemini-200 (200 MHz) spectrometer. Chemical shifts are given in parts per million (ppm) with tetramethylsilane as an internal standard, and coupling constants (J values) are given in Hertz (Hz) . Optical resolutions were recorded with a Jasco DIP-370 or P-1030 digital polarimeter. Elemental analyses were carried out by Takeda Analytical Research Laboratories, Ltd., and results obtained were within Ϯ0.4% of the theoretical values. Column chromatography was carried out on a silica gel column (Kieselgel 60, 63-200 mesh, Merck). Yields were not optimized.
2-(4-Nitrobenzyl)-1,3,2-dioxaphosphorinane 2-oxide (7) To a mixture of 6 (22.7 g, 105 mmol) and pyridine (17.8 ml, 220 mmol) in THF (500 ml) was added oxalyl chloride (19.2 ml, 220 mmol) at Ϫ78°C. The mixture was stirred at Ϫ78°C for 0.5 h and at room temperature for 1.5 h. The precipitated solid was removed by filtration, and the filtrate was concentrated in vacuo. To a solution of the residue in THF (500 ml) was added dropwise a solution of 1,3-propanediol (8.00 g, 105 mmol) in acetonitrile (30 ml) at Ϫ78°C. Then pyridine (17.8 ml, 220 mmol) was added to the mixture at Ϫ78°C, and the mixture was stirred at room temperature for 15 h. The precipitate was filtered off on a plug of MgSO 4 , and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (EtOAcAEEtOAc : MeOH : Et 3 Nϭ100 : 10 : 1) to give 7.00 g (26%) of 7 as colorless crystals, mp 144-145°C. 
4-[(2-Oxido-1,3,2-dioxaphosphorinan-2-yl)methyl]aniline (8a)
A mixture of 7 (7.00 g, 27.2 mmol) and 10% Pd-C (50% wet, 0.50 g) in EtOH (100 ml) and EtOAc (50 ml) was stirred at room temperature for 19 h under a hydrogen atmosphere. The catalyst was removed by filtration and the filtrate was concentrated in vacuo. The residue was purified by recrystallization from EtOAc-hexane to give 5.68 g (92%) of 8a as colorless crystals, mp 172-173°C. 1-(4-Nitrobenzyl)phosphorinane 1-Oxide (10a) To a mixture of nitric acid (1.94 ml) and sulfuric acid (15 ml) was added 9a 14) (5.39 g, 25.9 mmol) under ice cooling. It was stirred at 50°C for 2 d. The reaction mixture was poured into ice. The mixture was neutralized using aqueous ammonia, and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO 4 , and concentrated in vacuo. The residue was purified by column chromatography (EtOAc : EtOHϭ9 : 1AE2 : 1) to give 2.47 g (38%) of 10a as colorless crystals, mp 173-175°C. 1 2-(4-Nitrobenzyl)pyridine (10c) To a mixture of nitric acid (2.1 ml) and sulfuric acid (15 ml) was added 9c (4.5 ml, 28.0 mmol) under ice cooling. The mixture was stirred at 50°C for 5 min. The mixture was poured into ice, and the mixture was basified using aqueous ammonia. 2-Methyl-4-nitrobenzaldehyde (11b) A mixture of 1,2-dimethyl-4-nitrobenzene (25.68 g, 170 mmol), N-bromosuccinimide (NBS) (31.8 g, 179 mmol) and 2,2Ј-azobis(isobutyronitrile) (AIBN) (cat. amount) in EtOAc (400 ml) was refluxed for 7.5 h. NBS (10.5 g, 59.0 mmol) and AIBN (cat. amount) were added to the reaction mixture and the mixture was refluxed for 20 h. The mixture was concentrated in vacuo and the residue was purified by column chromatography (hexane : EtOAcϭ20 : 1) to give a pale yellow oil. A mixture of the oil and NaOAc (61.6 g, 751 mmol) in AcOH (200 ml) was stirred at 120°C for 7 h. The mixture was concentrated in vacuo. To the residue was added aqueous NaHCO 3 and the mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO 4 , and concentrated in vacuo. The residue was purified by column chromatography (hexane : EtOAcϭ10 : 1) to give a pale yellow oil. To a solution of the oil in MeOH (300 ml) was added NaOH (7.4 g, 185 mmol) at room temperature, and the mixture was refluxed for 2 h. The mixture was concentrated in vacuo and the residue was neutralized using 1 N HCl. The mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO 4 , and concentrated in vacuo. The residue was purified by column chromatography (hexane : EtOAcϭ2 : 1) to give yellow crystals. A mixture of the crystals and activated MnO 2 (8.90 g) in acetone (100 ml) was stirred at room temperature for 20 h. MnO 2 was removed by filtration, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (hexane : EtOAcϭ20 : 1) to give 1.38 g (5%) of 11b as colorless crystals. Compound 11b was used in the next reaction without further purification. 2-Chloro-4-nitrobenzaldehyde (11d) To a suspension of NaBH 4 (10.7 g, 283 mmol) in 1,2-dimethoxyethane (150 ml) was added 2-chloro-4-nitrobenzoyl chloride (25 g, 114 mmol) under ice cooling, and the mixture was stirred at room temperature for 1 h. The mixture was concentrated in vacuo. Water was added to the residue and the mixture was extracted with EtOAc. The organic layer was washed with 1 N HCl, 1 N NaOH, water and brine, dried over MgSO 4 , and concentrated in vacuo. A mixture of the residue (17.0 g) and activated MnO 2 (50.0 g) in acetone (200 ml) was stirred over night at room temperature. MnO 2 was removed by filtration, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (hexane : EtOAcϭ9 : 1) to give 12.1 g (58%) of 11d as yellow crystals. Compound 11d was used in the next reaction without further purification. (4-Nitrophenyl)(pyridin-2-yl)methanol (12a) To a solution of 2-bromopyridine (9.09 g, 57.5 mmol) in Et 2 O (200 ml) was added dropwise a solution of n-BuLi in hexane (1.6 M, 39.6 ml, 63.3 mmol) at Ϫ78°C. After being stirred at Ϫ78°C for 1 h under an argon atmosphere, a solution of 8a (8.70 g, 57.5 mmol) in tetrahydrofuran (THF) (50 ml) was added to the reaction mixture at Ϫ78°C. The mixture was stirred at Ϫ78°C for 3 h under an argon atmosphere. Water was added to the reaction mixture and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO 4 , and concentrated in vacuo. The residue was purified by column chromatography (toluene : EtOAcϭ10 : 1AE4 : 1AE2 : 1) and recrystallization from diisopropyl ether (i-Pr 2 O) to give 4.5 g (34%) of 9a as orange crystals, mp 114-115°C. 1 (4-Amino-2-chlorophenyl)(pyridin-2-yl)methanol (8l) To a solution of 12d (1.00 g, 4.05 mmol) in THF (15 ml), EtOH (15 ml) and water (15 ml) was added Na 2 S 2 O 4 (3.30 g, 19.0 mmol) at room temperature, and the mixture was stirred at room temperature for 0.5 h. The reaction mixture was concentrated in vacuo and the mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO 4 , and concentrated in vacuo to give 0.21 g (24%) of 8l as colorless crystals, mp 142-146°C (dec.). 1 H-NMR data of the chiral compounds were identical with those of 8e.
2-(4-
(
R)-3-Bromo-N-{4-[hydroxy(pyridin-2-yl)methyl]phenyl}benzamide ((R)-13)
To a solution of (R)-8e (0.50 g, 2.50 mmol) and Et 3 N (1.1 ml, 7.90 mmol) in THF (10 ml) was added 3-bromobenzoyl chloride (0.54 g, 2.46 mmol) under ice cooling. After being stirred at room temperature for 20 h, water was added to the mixture, and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO 4 , and concentrated in vacuo. The residue was purified by column chromatography (hexane : EtOAcϭ1 : 1AE2 : 1) to and recrystallization from EtOAc-i-Pr 2 O to give 349.9 mg (37%) of (R)-13 as pale yellow crystals, mp 153-154°C. [ 
2-(4-Fluorobenzoyl)-3-methylpyridine (16a)
A solution of 15a (5.14 g, 22.7 mmol) and K 2 CO 3 (2.90 g, 21.0 mmol) in dimethylsulfoxide (DMSO) (250 ml) and water (50 ml) was stirred at room temperature for 6 d under an oxygen atmosphere. The reaction mixture was poured into water and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO 4 , and concentrated in vacuo. The residue was purified by column chromatography (hexane : EtOAcϭ4 : 1) to give 5.17 g (quant.) of 16a as an orange oil. The following compounds (16b-d) were prepared from 15b-d by a method similar to that described for 16a.
2-(4-Fluorobenzoyl)-4-methylpyridine (16b)
Yield 55%, brown crystals (EtOAc-hexane), mp 98-100°C. 
4-Fluoro-N-methoxy-N-methyl-2-(trifluoromethyl)benzamide (18)
To a solution of 17 (6.70 g, 32.2 mmol) of THF (50 ml) was added SOCl 2 (3.40 ml, 46.6 mmol) and DMF (cat. amount) under ice cooling. After being stirred at room temperature for 1 h, the mixture was concentrated in vacuo. A solution of the residue in CHCl 2 (30 ml) was added dropwise to a solution of N,O-dimethylhydroxylamine hydrochloride (3.80 g, 39.0 mmol) and triethylamine (Et 3 N) (6.7 ml, 48.1 mmol) in CHCl 2 (50 ml) under ice cooling. The reaction mixture was stirred at room temperature for 24 h. Water was added to the reaction mixture and the mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO 4 , and concentrated in vacuo. The residue was purified by column chromatography (hexane : EtAOcϭ2 : 1) to give 9.7 g (quant) of 18 as a colorless oil.
1 H-NMR (CDCl 3 ) d: 3.36 (3H, s), 3.42 (3H, s), 7.26-7.47 (3H, m).
2-[4-Fluoro-2-(trifluoromethyl)benzoyl]pyridine (16e)
To a solution of 2-bromopyridine (4.10 g, 25.9 mmol) in Et 2 O (50 ml) was added dropwise a solution of n-BuLi in hexane (1.6 M, 19.4 ml, 31.0 mmol) at Ϫ78°C. The reaction mixture was stirred at Ϫ78°C under an argon atmosphere for 1 h. A solution of 18 (5.00 g, 19.9 mmol) in Et 2 O (50 ml) was added dropwise to the reaction mixture at Ϫ78°C. After being stirred at room temperature for 1.5 h, water was added to the reaction mixture, and the mixture was neutralized using 1 N HCl under ice cooling. The mixture was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO 4 , and concentrated in vacuo. The residue was purified by column chromatography (hexane : EtOAcϭ1 : 1) and recrystallization from hexane to give 3.40 g (63%) of 16e as brown crystals, mp 85-86°C. 54 mmol) in CH 2 Cl 2 (7.0 ml) was added oxalyl chloride (0.14 ml, 1.60 mmol) and DMF (cat. amount) under ice cooling. After being stirred at room temperature for 3 h, the mixture was concentrated in vacuo. A solution of the residue in THF (10 ml) was added dropwise a solution of 8a (0.13 g, 0.57 mmol) and Et 3 N (0.23 ml, 1.65 mmol) in THF (10 ml) under ice cooling. The mixture was stirred at room temperature for 14 h. The mixture was concentrated in vacuo, and water was added to the residue. The mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO 4 , and concentrated in vacuo. The residue was purified by recrystallization from EtOAc to give 0.227 g (87%) of 5a as colorless crystals. 89 mmol) in THF (10 ml) was added oxalyl chloride (0.12 ml, 1.38 mmol) and DMF (cat. amount) at room temperature. After being stirred at room temperature for 1 h, the mixture was concentrated in vacuo. A solution of the residue in THF (15 ml) was added to a solution of 8b (0.22 g, 0.98 mmol) and Et 3 N (0.25 ml, 1.79 mmol) in THF (5.0 ml) under ice cooling. After being stirred at room temperature for 4 h, water was added to the mixture, and the mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO 4 The following compounds (20a-c) were prepared from 19a and the corresponding anilines 8c-e by a method similar to that described for 5b. 92 mmol) in CH 2 Cl 2 (10 ml) was added mCPBA (70%, 0.25 g, 1.10 mmol) under ice cooling. After being stirred at room temperature for 70 h, aqueous Na 2 S 2 O 3 was added to the mixture, and the mixture was extracted with CH 2 Cl 2 . The organic layer was washed with aqueous NaHCO 3 and brine, dried over MgSO 4 , and concentrated in vacuo. The residue was purifed by column chromatography (EtOAc : EtOHϭ1 : 1) and recrystallization from CHCl 3 -EtOH to give 59.5 mg (14%) of 5c as colorless crystals. 1 The following compounds (5d-f) were prepared from 20b-d by a method similar to that described for 5c.
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